NEW YORK, Sept. 02, 2022 (GLOBE NEWSWIRE) — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Ampio Pharmaceuticals, Inc. (“Ampio” or “the Company”) AMPE and certain of its officers on behalf of all persons and entities that purchased or otherwise acquired Ampio securities between December 29, 2020 and August 3, 2022, both dates inclusive (the “Collection Period”). Such investors are encouraged to join this case by visiting the company’s website: www.bgandg.com/ampe.

This class action seeks damages against the defendants for alleged violations of federal securities laws.

The Complaint alleges that the Defendants made false and/or misleading statements and/or failed to disclose material adverse facts about the Company’s operations and prospects during the Class Period. Specifically, the defendants have: (1) exaggerated the Company’s true ability to successfully submit a Biologics License Application (BLA) for Ampio; (2) inflated results from Ampion’s AP-013 study (the company’s lead product with “unique immunomodulatory and anti-inflammatory effects” used to treat individuals with inflammatory conditions including but not limited to severe osteoarthritis of the knee (OAK)) and the timing of unblinding the data from the AP-013 study; and (3) that as a result of the foregoing, defendants’ statements about the Company’s business, operations and prospects were materially misleading and/or lacked any reasonable basis. As the true details emerged, the lawsuit alleges that investors suffered damage.

A class action lawsuit has already been filed. If you would like to see a copy of the complaint, you can visit the firm’s website: www.bgandg.com/ampe or you can contact Peretz Bronstein, Esq. or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Ampio, you have until October 17, 2022 to…